The 6th International Congress of Pathophysiology will enlarge the scope of the meeting
to reflect current trends in the evolution of pathophysiology and biological science such as the
progress in genomics. The ISP 2010 will present novel therapeutic targets based on this new
knowledge, future tools in prevention, and optimized therapy based on predictive genomics.
The 14th International SHR Symposium will offer the best opportunity for researchers and
clinical to meet and discuss critical issues on the ecogenomics of cardiometabolic diseases.
This year, Bio Pharma Asia Convention brings together 6 shows, 1 poster presentation, 3 site tours, 1 biotech showcase, 1 scientific symposium and 1 career seminar.
Do participate as a poster presenter in our Asia Research Institution Poster ShowcaseORparticipate as a visitor to theBio Pharma Convention.
Besides providing a great platform for you to present your successes in research findings and development. Bio Pharma Asia Convention has catered more than 20 hours combined networking opportunity to allow interactions between all professionals and delegates attending the event. This is where you can build relationships, strike partnerships, and facilitate knowledge exchange.
Submit your abstract to bio.sg@terrapinn.com and receive a complimentary pass to the Drug Discovery Technology World Asia 2010 conference.
Wellcome Trust Conference Centre,Hinxton, Cambridge, UK
Building on the success of the annual Wellcome Trust Scientific Conference Genomic Disorders meetings held at Hinxton since 2007, Genomic Disorders 2010 presents an exciting blend of genomic science and clinical medicine. Our meeting aims to bring together scientists and clinicians interested in genomic variation and its phenotypic effects. The pace of change accelerated during 2009 with the first studies using whole exome sequencing approaches to identify mutations causing genetic syndromes
This year’s meeting will discuss the latest findings relating to the genomic basis of human variation, congenital disorders and acquired diseases including complex traits. Highlights of this year’s programme include an overview of whole genome approaches to the study of genetic diseases, presentations on normal variation and mechanisms of genomic disorders, transcriptional control, models of genomic disorders and opportunities for therapy
Scientific Programme Committee:
Nigel Carter, Wellcome Trust Sanger Institute, UK Dian Donnai, University of Manchester
Helen Firth, Cambridge University Dept. of Medical Genetics, UK